Show simple item record

dc.contributor.authorVento, Alessandro
dc.contributor.authorde Persis, Simone
dc.contributor.authorDe Filippis, Sergio
dc.contributor.authorSchifano, Fabrizio
dc.contributor.authorNapoletano, Flavia
dc.contributor.authorCorkery, John Martin
dc.contributor.authorKotzalidis, Georgios D.
dc.date.accessioned2021-04-02T23:06:08Z
dc.date.available2021-04-02T23:06:08Z
dc.date.issued2021-03-31
dc.identifier.citationVento , A , de Persis , S , De Filippis , S , Schifano , F , Napoletano , F , Corkery , J M & Kotzalidis , G D 2021 , ' Treatment of kratom use disorder with a classical tricyclic antidepressant: A case report and review ' , Frontiers in Psychiatry , vol. 12 , 640218 . https://doi.org/10.3389/fpsyt.2021.640218
dc.identifier.issn1664-0640
dc.identifier.urihttp://hdl.handle.net/2299/24212
dc.description© 2021 Vento, de Persis, De Filippis, Schifano, Napoletano, Corkery and Kotzalidis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). https://creativecommons.org/licenses/by/4.0/
dc.description.abstractKratom or Mitragyna speciosa (Korth.) is an evergreen tree of the coffee family native to South-East Asia and Australasia. It is used by locals recreationally to induce stimulant and sedative effects and medically to soothe pain and opiate withdrawal. Its leaves are smoked, chewed, or infused, or ground to yield powders or extracts for use as liquids. It contains more than 40 alkaloids; among these, mitragynine and 7-hydroxymitragynine are endowed with variable mu, delta, and kappa opioid stimulating properties (with 7-hydroxymitragynine having a more balanced affinity), rhynchophylline, which is a non-competitive NMDA glutamate receptor antagonist, but is present in negligible quantities, and raubasine, which inhibits α1-adrenceptors preferentially over α2-adrenceptors, while the latter are bound by 7-hydroxymitragynine, while mitragynine counters 5-HT2A receptors. This complexity of neurochemical mechanisms may account for kratom’s sedative-analgesic and stimulant effects. It is commonly held that kratom at low doses is stimulant and at higher doses sedative, but no cut-off has been possible to define. Long-term use of kratom may produce physical and psychological effects that are very similar to its withdrawal syndrome, i.e., anxiety, irritability, mood, eating, and sleep disorders, other than physical symptoms resembling opiate withdrawal. Kratom’s regulatory status varies across countries; in Italy, both mitragynine and the entire tree and its parts are included among regulated substances. We describe the case of a patient who developed anxiety and dysphoric mood and insomnia while using kratom, with these symptoms persisting after withdrawal. He did not respond to a variety of antidepressant combinations and tramadol for various months, and responded after one month of clomipramine. Wellbeing persisted after discontinuing tramadol.en
dc.format.extent9
dc.format.extent277385
dc.language.isoeng
dc.relation.ispartofFrontiers in Psychiatry
dc.subjectKratom
dc.subjectMitragynine
dc.subjectsubstance use disorder
dc.subjectclomipramine
dc.subjectwithdrawal syndrome
dc.titleTreatment of kratom use disorder with a classical tricyclic antidepressant: A case report and reviewen
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
rioxxterms.versionofrecord10.3389/fpsyt.2021.640218
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record